Periodic Reporting for period 1 - MDLab Ginestra (A novel characterization- and reliability-oriented simulation software for dielectric-based nano-electronic devices)
Okres sprawozdawczy: 2015-02-01 do 2015-07-31
The specific objectives of the project are:
to assess the Technical feasibility of the product (testing prototype efficiency);
to assess “Ginestra” Economic viability (potential in terms of EU market penetration).
2) We carried out a market analysis –comprising risks and sensitivity analysis- to verify Ginestra economic viability in terms of market trends, competitors and competitive solutions, potential customers identification/description as well as exploitation model. Moreover, we developed a detailed Business Plan for the next 5 years, attached.
The outcome from these studies is significant with regard to:
• market growth: 11.9% from 2013 to 2014 (with a significant share in Europe).
• competitors and their solutions: there are no available products able to compete with Ginestra in terms of usage scope, technical features, user-friendliness).
• capability to respond to identified market (potential customers) needs.
Is given below a summary of expected revenues for the years 2016-2020:
- 2016: euro 227.000
- 2017: euro 516.000
- 2018: euro 1.482.000
- 2019: euro 3.856.000
- 2020: euro 9.588.000
Using “Ginestra”, customers can benefit of the following advantages:
● reduced time-to-market
● decrease technology development costs;
● simplify the calibration on new technology;
● improve quality monitoring;
● save time required for the “characterization”;
● optimize reliability mechanisms at the device level.